Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale
<sup>177</sup>Lu-DOTATATE for neuroendocrine tumours is considered a low-toxicity treatment and may therefore be combined with other pharmaceuticals to potentiate its efficacy. One approach is to add a poly-[ADP-ribose]-polymerase (PARP) inhibitor to decrease the ability of tumour cells...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
MDPI AG
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/a9754249b27b4e299cd42ae821706fd7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|